UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
40.23
+0.23 (0.57%)
At close: Jul 17, 2026, 4:00 PM EDT
41.03
+0.80 (1.99%)
After-hours: Jul 17, 2026, 4:38 PM EDT
UroGen Pharma Employees
UroGen Pharma had 298 employees as of March 31, 2026. The number of employees increased by 64 or 27.35% compared to the same quarter last year.
Employees
298
Change
64
Growth
27.35%
Revenue / Employee
$471,453
Profits / Employee
-$447,064
Market Cap
1.96B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 298 | 64 | 27.35% | 298 | 0 |
| Dec 31, 2025 | 291 | 56 | 23.83% | 291 | 0 |
| Sep 30, 2025 | 287 | 70 | 32.26% | 287 | 0 |
| Jun 30, 2025 | 253 | 50 | 24.63% | 253 | 0 |
| Mar 31, 2025 | 234 | 30 | 14.71% | 234 | 0 |
| Dec 31, 2024 | 235 | 34 | 16.92% | 235 | 0 |
| Sep 30, 2024 | 217 | 25 | 13.02% | 217 | 0 |
| Jun 30, 2024 | 203 | 10 | 5.18% | 203 | 0 |
| Mar 31, 2024 | 204 | 10 | 5.15% | 204 | 0 |
| Dec 31, 2023 | 201 | 1 | 0.50% | 198 | 3 |
| Sep 30, 2023 | 192 | -3 | -1.54% | 192 | 0 |
| Jun 30, 2023 | 193 | -8 | -3.98% | 193 | 0 |
| Mar 31, 2023 | 194 | 2 | 1.04% | 194 | 0 |
| Dec 31, 2022 | 200 | 5 | 2.56% | 200 | 0 |
| Sep 30, 2022 | 195 | -3 | -1.52% | 195 | 0 |
| Jun 30, 2022 | 201 | 11 | 5.79% | 201 | 0 |
| Mar 31, 2022 | 192 | 2 | 1.05% | 192 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Lakefront Biotherapeutics NV | 558 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 307 |
| Harmony Biosciences Holdings | 293 |
| Viridian Therapeutics | 252 |
| Kardigan | 241 |
| Monte Rosa Therapeutics | 187 |
URGN News
- 2 days ago - UroGen Pharma price target raised to $50 from $40 at Oppenheimer - TheFly
- 3 days ago - UroGen Pharma price target raised to $44 from $18 at Goldman Sachs - TheFly
- 3 days ago - UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103 - TheFly
- 3 days ago - UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103 - GlobeNewsWire
- 10 days ago - UroGen Pharma announces FDA clearance for UGN-501 IND application - TheFly
- 10 days ago - UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 26 days ago - UroGen Pharma Transcript: AGM 2026 - Transcripts
- 5 weeks ago - UroGen Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts